Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study

Bone Marrow Transplant. 2017 Feb;52(2):326-329. doi: 10.1038/bmt.2016.279. Epub 2016 Oct 31.

Authors

R F Duarte¹, I Sánchez-Ortega¹, M Arnan¹, B Patiño¹, J Ayats², A Sureda¹, M Cuenca-Estrella³

Affiliations

¹ Department of Hematology, Catalan Institute of Oncology-Hospital Duran i Reynals, Biomedical Research Institute of Bellvitge (Idibell), Barcelona, Spain.
² Department of Microbiology, Hospital Universitario de Bellvitge, Barcelona, Spain.
³ Department of Micology, Centro Nacional de Microbiología-Instituto de Salud Carlos III, Madrid, Spain.

PMID: 27797367
DOI: 10.1038/bmt.2016.279

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antifungal Agents / administration & dosage*
Female
Fungi
Galactose / analogs & derivatives
Hematologic Neoplasms* / blood
Hematologic Neoplasms* / therapy
Hematopoietic Stem Cell Transplantation*
Humans
Male
Mannans / blood*
Middle Aged
Mycoses* / blood
Mycoses* / drug therapy
Prospective Studies
Triazoles / administration & dosage*

Substances

Antifungal Agents
Mannans
Triazoles
galactomannan
posaconazole
Galactose